A Few Companies Bet On Continuing Role For Interferon Therapy In HCV
Executive Summary
Hepatitis C drug development is almost exclusively focused on small molecule oral therapies. Of the 54 compounds in clinical development, just two aim to improve upon injectable interferon, the molecule that forms the backbone of current standard of care. It would be tempting to write them off, but a funny thing happened on the way to the interferon-free future.
You may also be interested in...
Hepatitis C Marketing: Applying Primary Care Tactics To Specialty Products
The Food and Drug Administration's back-to-back approvals of Hepatitis C therapies from Merck & Co. and Vertex Pharmaceuticals set the stage for a specialty-focused marketing battle the likes of which the biopharma industry hasn't seen in years.
Hepatitis C Marketing: Applying Primary Care Tactics To Specialty Products
The Food and Drug Administration's back-to-back approvals of Hepatitis C therapies from Merck & Co. and Vertex Pharmaceuticals set the stage for a specialty-focused marketing battle the likes of which the biopharma industry hasn't seen in years.
EASL Preview: Dual Versus Quad Combinations
Data on oral hepatitis C drugs from Pharmasset, Gilead, Vertex, Bristol-Myers and others will be watched closely at the EASL International Liver Congress.